Form D · Biotechnology
Simplicia, Inc.
Boston, MA · CIK 0002148568
Offering snapshot reported Aug 13, 2026 · SEC filing
- Reported sold
- $600K Offering amount: $1.5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Jul 31, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 13, 2026 | Initial | $600,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594207
SAFEs
Source: Form D, filed Aug 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Katherine Arline | Director, Executive |
| Josepha Kaminski | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
56 Broad Street, Suite 96763
Boston, MA, 02109
Phone: 7173953871
Boston, MA, 02109
Phone: 7173953871